Venlafaxine in adults with attention-deficit/hyperactivity disorder

An open clinical trial

Robert L Findling, Michael A. Schwartz, Daniel J. Flannery, Michael J. Manos

Research output: Contribution to journalArticle

Abstract

Background: It is becoming commonly recognized that adults suffer from attention-deficit/hyperactivity disorder (ADHD). Since medications used in the past to treat adults with ADHD may be ineffective or poorly tolerated by some patients, it is important to determine if newly available medications can safely ameliorate symptoms of ADHD in adults. Method: An open clinical trial was undertaken to examine whether venlafaxine was safe and effective in the treatment of adults with ADHD. Ten subjects who met DSM-IV criteria for ADHD were enrolled in this 8-week trial. Individuals were started on 37.5 mg of venlafaxine b.i.d. If moderate ADHD symptoms persisted at the end of Week 4, the dose of venlafaxine was increased to 75 mg b.i.d. Assessments of ADHD symptomatology included the ADHD Rating Scale, Self-Report Version (ARS) and the Clinical Global Impressions (CGI) scale. Results: Nine patients completed the study. At the end of the study, 7 patients were receiving 37.5 mg b.i.d. of venlafaxine. Repeated measures ANOVA demonstrated that treatment with venlafaxine was associated with significant reductions in ADHD symptomatology (p <.02 for the ARS; p <.005 for the CGI). Of the 9 subjects who completed the trial, 7 were considered responders. Venlafaxine was well tolerated, and most patients experienced only mild side effects. Conclusion: Venlafaxine may be a promising agent for the treatment of ADHD in adults. Controlled clinical trials are needed to further examine this issue.

Original languageEnglish (US)
Pages (from-to)184-189
Number of pages6
JournalJournal of Clinical Psychiatry
Volume57
Issue number5
StatePublished - May 1996
Externally publishedYes

Fingerprint

Attention Deficit Disorder with Hyperactivity
Clinical Trials
Venlafaxine Hydrochloride
Controlled Clinical Trials
Diagnostic and Statistical Manual of Mental Disorders
Self Report
Analysis of Variance
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Venlafaxine in adults with attention-deficit/hyperactivity disorder : An open clinical trial. / Findling, Robert L; Schwartz, Michael A.; Flannery, Daniel J.; Manos, Michael J.

In: Journal of Clinical Psychiatry, Vol. 57, No. 5, 05.1996, p. 184-189.

Research output: Contribution to journalArticle

Findling, Robert L ; Schwartz, Michael A. ; Flannery, Daniel J. ; Manos, Michael J. / Venlafaxine in adults with attention-deficit/hyperactivity disorder : An open clinical trial. In: Journal of Clinical Psychiatry. 1996 ; Vol. 57, No. 5. pp. 184-189.
@article{693b52ee3aee4e418fc6f22346787011,
title = "Venlafaxine in adults with attention-deficit/hyperactivity disorder: An open clinical trial",
abstract = "Background: It is becoming commonly recognized that adults suffer from attention-deficit/hyperactivity disorder (ADHD). Since medications used in the past to treat adults with ADHD may be ineffective or poorly tolerated by some patients, it is important to determine if newly available medications can safely ameliorate symptoms of ADHD in adults. Method: An open clinical trial was undertaken to examine whether venlafaxine was safe and effective in the treatment of adults with ADHD. Ten subjects who met DSM-IV criteria for ADHD were enrolled in this 8-week trial. Individuals were started on 37.5 mg of venlafaxine b.i.d. If moderate ADHD symptoms persisted at the end of Week 4, the dose of venlafaxine was increased to 75 mg b.i.d. Assessments of ADHD symptomatology included the ADHD Rating Scale, Self-Report Version (ARS) and the Clinical Global Impressions (CGI) scale. Results: Nine patients completed the study. At the end of the study, 7 patients were receiving 37.5 mg b.i.d. of venlafaxine. Repeated measures ANOVA demonstrated that treatment with venlafaxine was associated with significant reductions in ADHD symptomatology (p <.02 for the ARS; p <.005 for the CGI). Of the 9 subjects who completed the trial, 7 were considered responders. Venlafaxine was well tolerated, and most patients experienced only mild side effects. Conclusion: Venlafaxine may be a promising agent for the treatment of ADHD in adults. Controlled clinical trials are needed to further examine this issue.",
author = "Findling, {Robert L} and Schwartz, {Michael A.} and Flannery, {Daniel J.} and Manos, {Michael J.}",
year = "1996",
month = "5",
language = "English (US)",
volume = "57",
pages = "184--189",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5",

}

TY - JOUR

T1 - Venlafaxine in adults with attention-deficit/hyperactivity disorder

T2 - An open clinical trial

AU - Findling, Robert L

AU - Schwartz, Michael A.

AU - Flannery, Daniel J.

AU - Manos, Michael J.

PY - 1996/5

Y1 - 1996/5

N2 - Background: It is becoming commonly recognized that adults suffer from attention-deficit/hyperactivity disorder (ADHD). Since medications used in the past to treat adults with ADHD may be ineffective or poorly tolerated by some patients, it is important to determine if newly available medications can safely ameliorate symptoms of ADHD in adults. Method: An open clinical trial was undertaken to examine whether venlafaxine was safe and effective in the treatment of adults with ADHD. Ten subjects who met DSM-IV criteria for ADHD were enrolled in this 8-week trial. Individuals were started on 37.5 mg of venlafaxine b.i.d. If moderate ADHD symptoms persisted at the end of Week 4, the dose of venlafaxine was increased to 75 mg b.i.d. Assessments of ADHD symptomatology included the ADHD Rating Scale, Self-Report Version (ARS) and the Clinical Global Impressions (CGI) scale. Results: Nine patients completed the study. At the end of the study, 7 patients were receiving 37.5 mg b.i.d. of venlafaxine. Repeated measures ANOVA demonstrated that treatment with venlafaxine was associated with significant reductions in ADHD symptomatology (p <.02 for the ARS; p <.005 for the CGI). Of the 9 subjects who completed the trial, 7 were considered responders. Venlafaxine was well tolerated, and most patients experienced only mild side effects. Conclusion: Venlafaxine may be a promising agent for the treatment of ADHD in adults. Controlled clinical trials are needed to further examine this issue.

AB - Background: It is becoming commonly recognized that adults suffer from attention-deficit/hyperactivity disorder (ADHD). Since medications used in the past to treat adults with ADHD may be ineffective or poorly tolerated by some patients, it is important to determine if newly available medications can safely ameliorate symptoms of ADHD in adults. Method: An open clinical trial was undertaken to examine whether venlafaxine was safe and effective in the treatment of adults with ADHD. Ten subjects who met DSM-IV criteria for ADHD were enrolled in this 8-week trial. Individuals were started on 37.5 mg of venlafaxine b.i.d. If moderate ADHD symptoms persisted at the end of Week 4, the dose of venlafaxine was increased to 75 mg b.i.d. Assessments of ADHD symptomatology included the ADHD Rating Scale, Self-Report Version (ARS) and the Clinical Global Impressions (CGI) scale. Results: Nine patients completed the study. At the end of the study, 7 patients were receiving 37.5 mg b.i.d. of venlafaxine. Repeated measures ANOVA demonstrated that treatment with venlafaxine was associated with significant reductions in ADHD symptomatology (p <.02 for the ARS; p <.005 for the CGI). Of the 9 subjects who completed the trial, 7 were considered responders. Venlafaxine was well tolerated, and most patients experienced only mild side effects. Conclusion: Venlafaxine may be a promising agent for the treatment of ADHD in adults. Controlled clinical trials are needed to further examine this issue.

UR - http://www.scopus.com/inward/record.url?scp=0029891154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029891154&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 184

EP - 189

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 5

ER -